Smoking and Schizophrenia: Is Symptom Profile Related to Smoking and which Antipsychotic Medication is of Benefit in Reducing Cigarette use?

Barnes, Mark; Lawford, Bruce R.; Burton, Simon C.; Heslop, Karen; Noble, Ernest P.; Hausdorf, Karrin; Young, Ross McD.

doi:10.1080/j.1440-1614.2006.01841.x

Cited by 83 publications

(54 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Smokers in the galantamine group had higher symptom scores and were slightly older. However, these group differences likely had no effects on smoking behavior as the galantamine treatment arm did not significantly improve symptoms (Boggs et al 2007) and symptom severity has not been previously associated with smoking in schizophrenia (Barnes et al 2006). In addition, symptom severity was not associated with changes in expired CO or FTND scores in the current study.…”

Section: Discussioncontrasting

confidence: 46%

“…Cigarette smoking may partially represent an attempt at self-medication to control symptoms not addressed by antipsychotic medications (Simosky et al 2002). Studies of the effects of nicotine in people with schizophrenia have shown improvements in numerous areas including learning and memory, eye tracking, prepulse inhibition of acoustic startle response and P50 sensory inhibition (Levin 1992, Rezvani and Levin 2001, Olincy et al 1998, Hong et al 2007, Adler et al 1993 or to control medication side effects (Barnes et al 2006). There is evidence implicating the nicotinic cholinergic and specifically the α7 and α4β2 nicotinic receptor systems in the pathophysiology of schizophrenia (Martin andFreedman 2007, Levin andRezvani 2007).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia

Kelly

McMahon

Weiner

et al. 2008

Schizophrenia Research

View full text Add to dashboard Cite

Cigarette smoking is schizophrenia is prevalent and may be due to self-medicating attempts to improve cognitive deficits related to α7 and α4β2 nicotinic receptor dysregulation. Galantamine is an acetylcholinesterase inhibitor that acts as a positive allosteric modulator of nicotine acetylcholine receptors including both the α4β2 and α7 subunits. In a double blind randomized clinical trial galantamine was compared to placebo for its effects on cognitive functioning in people with schizophrenia. This manuscript reports findings for galantamine's effect on smoking behavior in people from this 12-week trial who were smokers (18 galantamine, 25 placebo). Expired CO was measured every 2 weeks and the Fagerström Test for Nicotine Dependence (FTND) was administered at baseline and endpoint. Expired CO measures in galantamine subjects were 23.0 ± 9.7 ppm and 21.1 ± 10.3 ppm at baseline and Week 12, respectively, compared to 20.1 ± 8.5 ppm and 21.0 ±10.3 ppm at baseline and Week 12 in placebo subjects. The mean tau-b correlation between expired CO level and visit was −0.05 ± 0.41 in the galantamine group and 0.13 ± 0.42 in the placebo group (F=0.73, df=1,38, p=0.40), suggesting that there were no trends toward increased or decreased smoking in either group. Mean FTND scores in the galantamine group were 4.9 ± 2.5 at baseline and 5.2 ± 2.2 at week 12, compared to 4.1 ± 2.6 at baseline and 3.7 ± 2.6 at Week 12 in the placebo group (Mantel-Haenszel Χ 2 = 5.53, df=1, p=0.019), for an effect size of 0.4. These results suggest that galantamine has no effect on cigarette smoking and that during galantamine treatment nicotine dependency scores worsen.

show abstract

Section: Discussioncontrasting

confidence: 46%

mentioning

confidence: 99%

Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia

Kelly

McMahon

Weiner

et al. 2008

Schizophrenia Research

View full text Add to dashboard Cite

show abstract

“…There was no indication of associated deterioration in symptoms or functioning during a smoking cessation trial involving 298 smokers with psychosis who received NRT, motivational interviewing and CBT (Baker et al, 2006). However, akathisia can occur after smoking cessation (Barnes et al, 2006).…”

Section: Schizophreniamentioning

confidence: 94%

“…One found limited evidence of a reduction in negative symptoms (Dalack & MeadorWoodruff, 1996); in another, only 17% of participants reported that smoking improved their psychotic symptoms (Kelly & McCreadie, 2000); in a third, smoking was not associated with improvement in positive, negative, cognitive or mood symptoms in 146 people with schizophrenia (Barnes et al, 2006).…”

Section: Smoking As Self-medication In Schizophreniamentioning

confidence: 99%

Smoking by people with mental illness and benefits of smoke-free mental health services

Campion¹,

Checinski²,

Nurse³

et al. 2008

Adv. psychiatr. treat

View full text Add to dashboard Cite

Smoking is the largest single cause of preventable illness in the UK. Those with mental health problems smoke significantly more and are therefore at greater risk. The new Health Act (2006) will require mental health facilities in England to be completely smoke-free by 1st July 2008. This article reviews the current literature regarding how smoking affects both the physical and mental well-being of people with mental health problems. It also considers the effects of smoke-free policy in mental health settings.Jonathan Campion is a specialist psychiatry registrar on the St George's Psychiatry Training Scheme in London

show abstract

“…Nicotine has also been shown to alleviate extrapyramidal symptoms caused by neuroleptics (13,14). Less akathisia has been reported in smokers (15). Atypical antipsychotics with a similar mechanism of action have also been shown to reduce smoking in schizophrenic patients (16).…”

Section: Introductionmentioning

confidence: 99%

Cigarette Consumption and Related Factors in Schizophrenia, Schizoaffective Disorder and Delusional Disorder

Boşgelmez¹,

Yıldız²

2017

Dusunen Adam

View full text Add to dashboard Cite

Cigarette consumption and related factors in schizophrenia, schizoaffective disorder and delusional disorderObjective: The present study is designed to assess the rate of smoking and related factors in outpatients with schizophrenia, schizoaffective disorder and delusional disorder.Methods: Medical records of 541 patients, diagnosed with schizophrenia, schizoaffective disorder and delusional disorder according to DSM-IV were examined retrospectively. Daily cigarette consumption, sociodemographic characteristics and medical data of the patients were evaluated. Logistic regression analysis was conducted to determine the factors associated with smoking. Correlation analysis was performed to assess factors related with daily cigarette consumption.Results: Of the 541 patients, 242 (44.7%) were current smokers. Smoking rate was significantly higher in males. Although there were differences in sociodemographic characteristics and disorder related variables, there was no difference in smoking rates of patients with schizophrenia, schizoaffective disorder, and delusional disorder. In logistic regression analysis it was shown that smoking was associated with male gender and violent behavior after illness onset in psychotic disorders. Correlation analysis showed that mean number of daily consumed cigarettes correlated moderately with the duration of the illness. Conclusions:In the study, similar smoking rates were found between psychotic disorders. Smoking is strongly related with male gender and violent behavior after onset of illness. The relation between smoking and violent behavior emerges as a new field deserving further investigation.Keywords: Delusional disorder, psychotic disorders, schizoaffective disorder, schizophrenia, smoking ÖZET Şizofreni, şizoaffektif bozukluk ve sanrılı bozuklukta sigara tüketimi ve ilişkili etmenler Amaç: Bu çalışmada ayaktan tedavi gören şizofreni, şizoaffektif bozukluk ve sanrılı bozukluk hastalarında sigara kullanma sıklığını ve bununla ilişkili etmenleri belirlemek amaçlanmıştır.Yöntem: DSM-IV'e göre şizofreni, şizoaffektif bozukluk ve sanrılı bozukluk tanısı alan 541 hastanın dosyası geriye dönük olarak incelendi. Hastaların günlük sigara kullanma miktarı, nüfus özellikleri ve hastalıklarıyla ilişkili dosya verileri değerlendirildi. Sigara içimiyle ilişkili etmenleri belirlemek için lojistik regresyon, günlük sigara tüketimi miktarıyla ilişkili etmenleri araştırmak için korelasyon analizi kullanıldı.Bulgular: Çalışmaya dahil edilen 541 hastanın %44.7'sinin (n=242) düzenli olarak sigara kullandığı belirlendi.Erkeklerin sigara kullanma oranı kadınlarınkinden anlamlı derecede yüksekti. Şizofreni, şizoaffektif bozukluk ve sanrılı bozukluk hastalarında çalışmada ele alınan nüfus özellikleri ve hastalıklarıyla ilişkili değişkenler açısından farklılıklar olmasına rağmen, sigara içimi sıklığı bakımından fark saptanmadı. Lojistik regresyon analizi uygulandığında psikotik bozukluklarda sigara kullanımının, erkek cinsiyet ve hastalandıktan sonraki şiddet davranışı ile ilişkili olduğu sa...

show abstract

Smoking and Schizophrenia: Is Symptom Profile Related to Smoking and which Antipsychotic Medication is of Benefit in Reducing Cigarette use?

Cited by 83 publications

References 46 publications

Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia

Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia

Smoking by people with mental illness and benefits of smoke-free mental health services

Cigarette Consumption and Related Factors in Schizophrenia, Schizoaffective Disorder and Delusional Disorder

Contact Info

Product

Resources

About